Article Contents ::
- 1 Details About Generic Salt :: Leucovor
- 2 Main Medicine Class:: Folic acid derivative
- 3 (loo-koe-VORE-in KAL-see-uhm) Wellcovorin, Lederle Leucovorin Calcium Class: Folic acid derivative
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Leucovor
Main Medicine Class:: Folic acid derivative
(loo-koe-VORE-in KAL-see-uhm)
Wellcovorin, Lederle Leucovorin Calcium
Class: Folic acid derivative
Drugs Class ::
Action Acts as antidote to drugs that antagonize folic acid, such as methotrexate.
Indications for Drugs ::
Indications
Oral and parenteral: Treatment to diminish toxicity and counteract effect of overdosage of folic acid antagonists. Parenteral: Treatment of megaloblastic anemia due to folic acid deficiency when oral therapy is not feasible.
Drug Dose ::
Route/Dosage
Colorectal Cancer
ADULTS: IV Either 200 mg/m2 followed by 5-fluorouracil (5-FU) 370 mg/m2 or 20 mg/m2 followed by 5-FU 425 mg/m2 qd for 5 days.
Leucovorin Rescue
ADULTS: PO/IV/IM 10 mg/m2 q 6 hr for 10 doses.
Megaloblastic Anemia Due to Folic Acid Deficiency
ADULTS: IV/IM 1 mg/day.
Contraindication ::
Contraindications Pernicious anemia and other megaloblastic anemias secondary to vitamin B 12 deficiency.
Drug Precautions ::
Precautions
Pregnancy: Category C. Lactation: Undetermined. Benzyl alcohol: Present in 1 mL amp and some diluents. Benzyl alcohol has been associated with fatal “gasping syndrome” in premature infants. 5-FU toxicity: Leucovorin enhances toxicity of 5-FU; dosage should be decreased. Administer only under supervision of physician experienced in use of antimetabolite cancer chemotherapy.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
OTHER: Hypersensitivity, including anaphylaxis and urticaria. No other adverse reactions have been attributed to leucovorin alone.
Drug Mode of Action ::
Action Acts as antidote to drugs that antagonize folic acid, such as methotrexate.
Drug Interactions ::
Interactions
Barbiturates, hydantoins (eg, phenytoin), primidone: May decrease anticonvulsant activity. Fluorouracil: Enhances toxicity of fluorouracil. Methotrexate: May decrease efficacy of intrathecal methotrexate.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Ensure that baseline laboratory values, including liver and renal function tests, CBC and platelet count, have been obtained before beginning therapy and monitor during treatment.
- Ensure that daily methotrexate levels are obtained when leucovorin is used for high-dose methotrexate rescue.
- Keep patient well hydrated. Monitor I&O carefully during treatment.
Drug Storage/Management ::
Administration/Storage
- When drug is given for leucovorin rescue after high-dose methotrexate therapy, administer first dose 24 hr after beginning of methotrexate infusion.
- When drug is given as antidote for inadvertent overdosage of folic acid antagonists (eg, methotrexate), administer as soon as overdose is detected, preferably within first hour.
- Reconstitute parenteral solution using Bacteriostatic Water for Injection or Sterile Water for Injection. Bacteriostatic water mixtures must be used within 7 days; sterile water mixtures, immediately. If doses > 10 mg/m2 are needed, reconstitute with Sterile Water for Injection.
- Administer IV solution slowly, at rate of < 160 mg/min, due to calcium content.
- If necessary, further dilution with 100 to 500 mL dextrose or saline solutions for intermittent infusion is possible.
- Tablets can be crushed if necessary.
- Store at room temperature and protect from light.
Drug Notes ::
Patient/Family Education
- Instruct patient not to double up doses, and to notify physician if dose is missed.
- Instruct patient to report the following symptoms to physician: Nausea, vomiting, diarrhea, sores in mouth, fatigue, difficulty breathing or skin disorders.
- Advise patient to notify physician if unable to keep dose down (ie, if vomiting occurs). Patient may need IM or IV therapy instead of oral medication.